Skip to Content
Merck
All Photos(1)

Key Documents

Safety Information

PHR1526

Supelco

Dexamethasone

Pharmaceutical Secondary Standard; Certified Reference Material

Synonym(s):

Dexamethasone, (11β,16α)-9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione, 9α-Fluoro-16α-methyl-11β,17α,21-trihydroxy-1,4-pregnadiene-3,20-dione, 9α-Fluoro-16α-methylprednisolone, Prednisolone F

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C22H29FO5
CAS Number:
Molecular Weight:
392.46
Beilstein:
2066651
EC Number:
MDL number:
UNSPSC Code:
41116107
PubChem Substance ID:
NACRES:
NA.24

biological source

synthetic

Quality Level

grade

certified reference material
pharmaceutical secondary standard

Agency

BP
EP
USP
traceable to BP 578
traceable to Ph. Eur. D0700000
traceable to USP 1176007

vapor pressure

<0.0000001 kPa ( 25 °C)

API family

dexamethasone

CofA

current certificate can be downloaded

packaging

pkg of 1 g

storage condition

protect from light

technique(s)

HPLC: suitable
gas chromatography (GC): suitable

color

white

mp

262-264 °C (lit.)

solubility

DMSO: soluble
acetone: sparingly soluble
chloroform: slightly soluble
dioxane: soluble
ethanol: sparingly soluble
ether: very slightly soluble
methanol: sparingly soluble
water: practically insoluble

application(s)

pharmaceutical (small molecule)

format

neat

shipped in

ambient

storage temp.

2-30°C

SMILES string

C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO

InChI

1S/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1

InChI key

UREBDLICKHMUKA-CXSFZGCWSA-N

Gene Information

human ... NR3C1(2908)

Looking for similar products? Visit Product Comparison Guide

General description

Dexamethasone is a corticosteroid medication, with anti-inflammatory activity. It is widely used for inflammatory ocular conditions and for the treatment of skin-allergic reactions.
Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards.

Application

Dexamethasone may be used as a pharmaceutical reference standard for the quantification of the analyte in pharmaceutical formulations using voltammentric techniques and reversed-phase high-performance liquid chromatography technique.
These Secondary Standards are qualified as Certified Reference Materials. These are suitable for use in several analytical applications including but not limited to pharma release testing, pharma method development for qualitative and quantitative analyses, food and beverage quality control testing, and other calibration requirements.

Biochem/physiol Actions

Glucocorticoid anti-inflammatory agent. Regulates T cell survival, growth, and differentiation. Inhibits the induction of nitric oxide synthase.

Analysis Note

These secondary standards offer multi-traceability to the USP, EP and BP primary standards, where they are available.

Other Notes

This Certified Reference Material (CRM) is produced and certified in accordance with ISO 17034 and ISO/IEC 17025. All information regarding the use of this CRM can be found on the certificate of analysis.

Footnote

To see an example of a Certificate of Analysis for this material enter LRAC2894 in the slot below. This is an example certificate only and may not be the lot that you receive.

Recommended products

Find a digital Reference Material for this product available on our online platform ChemisTwin® for NMR. You can use this digital equivalent on ChemisTwin® for your sample identity confirmation and compound quantification (with digital external standard). An NMR spectrum of this substance can be viewed and an online comparison against your sample can be performed with a few mouseclicks. Learn more here and start your free trial.

related product

Product No.
Description
Pricing

Pictograms

Health hazard

Signal Word

Danger

Hazard Statements

Hazard Classifications

Repr. 1B

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Regulatory Listings

Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.

JAN Code

PHR1526-1G-PW:
PHR1526-1G:


Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Simultaneous determination of dexamethasone and moxifloxacin in pharmaceutical formulations using stability indicating HPLC method
Razzaq NS, et al.
Arabian Journal of Chemistry, 10(3), 321-328 (2017)
Determination of prednisolone, dexamethasone and hydrocortisone in pharmaceutical formulations and biological fluid samples by voltammetric techniques using b-cyclodextrin modified carbon paste electrode
Balaji K, et al.
African Journal of Pharmacy and Pharmacology, 2(8), 157-166 (2008)
S Choi et al.
British journal of anaesthesia, 112(3), 427-439 (2014-01-15)
Brachial plexus nerve blocks (BPBs) have analgesic and opioid sparing benefits for upper extremity surgery. Single-injection techniques are limited by the pharmacological duration and therapeutic index of local anaesthetics (LAs). Continuous catheter techniques, while effective can present management challenges. Off-label
Sara Bringhen et al.
Blood, 124(1), 63-69 (2014-05-24)
This multicenter, open-label phase 2 trial determined the safety and efficacy of carfilzomib, a novel and irreversible proteasome inhibitor, in combination with cyclophosphamide and dexamethasone (CCyd) in patients with newly diagnosed multiple myeloma (NDMM) ≥65 years of age or who
A Keith Stewart et al.
The New England journal of medicine, 372(2), 142-152 (2014-12-09)
Lenalidomide plus dexamethasone is a reference treatment for relapsed multiple myeloma. The combination of the proteasome inhibitor carfilzomib with lenalidomide and dexamethasone has shown efficacy in a phase 1 and 2 study in relapsed multiple myeloma. We randomly assigned 792

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service